NovaBridge Biosciences (NBP) director reports 2025 employee stock option grant

Rhea-AI Filing Summary

NovaBridge Biosciences director Emmett Cunningham reported an initial holding of employee stock options linked to 120,000 Ordinary Shares. These 2025 Employee Share Options carry an exercise price of $3.2100 per share and expire on February 17, 2036.

The option was granted on February 17, 2026 and vests in three equal annual installments starting on the first anniversary of the grant date. The footnotes state that Ordinary Shares may be represented by ADSs, with 10 ADSs representing 23 Ordinary Shares, and that the underlying share count and exercise price are expressed in terms of ADSs.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cunningham Emmett

Role Director

Type	Security	Shares	Price	Value
holding	2025 Employee Share Option (right to buy)	--	--	--

Holdings After Transaction: 2025 Employee Share Option (right to buy) — 120,000 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Number of underlying securities and exercise price expressed in terms of ADSs. The option was granted on February 17, 2026. The option vests and becomes exercisable in three equal annual installments beginning on the first anniversary of the grant date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cunningham Emmett

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2025 Employee Share Option (right to buy)	(3)	02/17/2036	Ordinary Shares(1)	120,000(2)	$3.21(2)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Number of underlying securities and exercise price expressed in terms of ADSs.

3. The option was granted on February 17, 2026. The option vests and becomes exercisable in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position did Emmett Cunningham report in NovaBridge Biosciences (NBP) Form 3?

Emmett Cunningham reported holding a 2025 Employee Share Option tied to 120,000 NovaBridge Biosciences Ordinary Shares. This is an initial ownership report, showing his derivative-based exposure rather than a new market purchase or sale of stock.

What are the key terms of Emmett Cunningham’s 2025 Employee Share Option at NovaBridge Biosciences (NBP)?

The 2025 Employee Share Option has an exercise price of $3.2100 per share and expires on February 17, 2036. It is linked to 120,000 underlying Ordinary Shares, providing long-dated equity exposure for the director through this option grant.

How does the vesting schedule work for Emmett Cunningham’s NovaBridge Biosciences (NBP) option grant?

The option granted on February 17, 2026 vests and becomes exercisable in three equal annual installments. Vesting begins on the first anniversary of the grant date, creating a three-year vesting period tied to continued service with the company.

How are NovaBridge Biosciences (NBP) Ordinary Shares represented by ADSs in this Form 3 filing?

Ordinary Shares may be represented by American Depositary Shares, or ADSs. The filing states that each 10 ADSs represent 23 Ordinary Shares, and notes that the number of underlying securities and the exercise price are expressed in terms of ADSs.

Did Emmett Cunningham buy or sell NovaBridge Biosciences (NBP) shares in this Form 3?

The Form 3 does not report a buy or sell transaction; it reports an existing holding of a 2025 Employee Share Option. This establishes Cunningham’s initial derivative ownership position as a director, rather than documenting an open-market trade in the stock.